Carisma Therapeutics Inc. announced changes to its Board of Directors, effective October 31, 2024. Sohanya Cheng, MBA, was appointed to the Board, bringing over 20 years of experience in biopharmaceutical commercialization and research, with a strong focus on oncology. Her expertise is expected to be instrumental in advancing the company's portfolio and strengthening its foundation.
Ms. Cheng currently serves as EVP, Chief Commercial Officer, and Head of Business Development at Karyopharm Therapeutics. Her previous roles include Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals, and over a decade at Amgen in various oncology leadership positions. She holds an MBA from MIT Sloan School of Management and degrees from the University of Cambridge.
Concurrently, Michael Torok informed the Board of his intention to step down as a member, effective October 31, 2024, due to other professional commitments. The company expressed gratitude for his valuable service and wished him well in his next chapter.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.